文献速递免疫规划传染病防控与疫情报告

免疫增强剂CVC1302提升猪口蹄疫疫苗免疫效果与保护力

The immunopotentiator CVC1302 enhances immune efficacy and protective ability of foot-and-mouth disease virus vaccine in pigs.
PubMed 文献 · Vaccine · 2018-11-20

研究在8周龄仔猪中评估免疫增强剂CVC1302对口蹄疫灭活疫苗的免疫增强特性。接种后28天,CVC1302组的液相阻断ELISA抗体、IgG1、IgG2及四种细胞因子水平显著高于单独疫苗组,抗体持续至少6个月。攻毒后CVC1302组病毒RNA拷贝数更低,PD50为15.85,高于疫苗组的10.96。

要点

  • CVC1302显著提高口蹄疫疫苗的抗体滴度和细胞因子水平。
  • CVC1302组抗体持续至少6个月,滴度>7.8 log2。
  • CVC1302提高PD50至15.85,增强攻毒保护。

核心结论

  • CVC1302可增强猪口蹄疫疫苗的免疫效果和保护能力。

研究设计与样本

  • 8周龄仔猪接种口蹄疫灭活疫苗,设单独疫苗组和添加CVC1302组,检测28天抗体、IgG、细胞因子及攻毒后PD50和病毒RNA。

主要发现

  • 接种后28天,CVC1302组LPB-ELISA抗体、IgG1、IgG2及IL-2、IL-4、IL-6、IFN-γ水平显著高于疫苗组。
  • CVC1302组抗体滴度>7.8 log2,持续至少6个月。
  • 三种剂量下CVC1302组LPB-ELISA和中和抗体滴度均显著高于同剂量疫苗组(p<0.05)。
  • 攻毒后3天和10天,CVC1302组病毒特异性RNA拷贝数低于疫苗组。
  • CVC1302组PD50为15.85,高于疫苗组的10.96;1/9剂量疫苗组仅3/5猪保护。

关键数值与推荐

  • CVC1302组PD50为15.85,疫苗组为10.96。
  • CVC1302组抗体滴度>7.8 log2,持续至少6个月。
  • 1/9剂量疫苗组保护率为3/5。

临床怎么用

  • 在猪口蹄疫免疫中,添加CVC1302可提升抗体应答和攻毒保护,尤其低剂量疫苗时可能改善保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunological enhancement characteristics of the immunopotentiator CVC1302 were evaluated for foot-and-mouth disease virus (FMDV) inactivated vaccine in pigs. Eight-week-old piglets were vaccinated with the foot-and-mouth disease (FMD) vaccine alone (FMD-vaccine group) or with the addition of CVC1302 (FMD-CVC1302 group), and the serum liquid phase blocking ELISA (LPB-ELISA) antibody titers, IgG1 and IgG2 levels, and the levels of four cytokines secreted by peripheral blood lymphocytes were measured at 28 days post vaccination (dpv). In the FMD-CVC1302 group, the LPB-ELISA antibody titers, IgG1, and IgG2 titers, and IL-2, IL-4, IL-6, and IFN-γ levels at 28 dpv were significantly higher than those in the FMD-vaccine group. The FMD-CVC1302 group had long-lasting antibody titers (>7.8 log2), lasting for at least 6 months. In addition, piglets were vaccinated with or without addition of CVC1302 to the FMD vaccine at three different doses (1, 1/3, and 1/9 of the standard vaccine dose) and the serum LPB-ELISA antibody and serum neutralizing (SN) antibody titers were detected at 28 dpv. Then all pigs were challenged with virulent FMDV for PD50 value, and the levels of FMDV-specific RNA copies for the two full-dose groups at 3 and 10 days post challenge (dpc) were measured. The LPB-ELISA and SN antibody titers for the three doses in the FMD-CVC1302 groups were significantly higher than those in the FMD-vaccine groups at the same doses (p < 0.05). Post-virus challenge, the FMDV-specific RNA copy number in the FMD-CVC1302 group was lower than that in the FMD-vaccine group at 3 and 10 dpc. The PD50 value was 15.85 for the FMD-CVC1302 group, which was obviously higher than that for the FMD-vaccine group (10.96), and in the 1/9-dose of FMD-vaccine group only 3/5 pigs were protected. These results indicate that CVC1302 can enhance the immune efficacy and protective ability of the FMD vaccine in pigs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chen J, Yu X, Zheng Q, et al. The immunopotentiator CVC1302 enhances immune efficacy and protective ability of foot-and-mouth disease virus vaccine in pigs. Vaccine. 2018. PMID: 30470640. doi:10.1016/j.vaccine.2018.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。